Skip to main content
Top
Published in: AIDS Research and Therapy 1/2020

Open Access 01-12-2020 | HIV Drug | Research

Pretreatment resistance mutations and treatment outcomes in adults living with HIV-1: a cohort study in urban Malawi

Authors: F. Neuhann, A. de Forest, E. Heger, A. Nhlema, C. Scheller, R. Kaiser, H. M. Steffen, H. Tweya, G. Fätkenheuer, S. Phiri

Published in: AIDS Research and Therapy | Issue 1/2020

Login to get access

Abstract

Background

Pre-treatment drug resistance (PDR) among antiretroviral drug-naïve people living with HIV (PLHIV) represents an important indicator for the risk of treatment failure and the spread of drug resistant HIV variants. We assessed the prevalence of PDR and treatment outcomes among adults living with HIV-1 in Lilongwe, Malawi.

Methods

We selected 200 participants at random from the Lighthouse Tenofovir Cohort Study (LighTen). Serum samples were drawn prior to treatment initiation in 2014 and 2015, frozen, and later analyzed for the presence of HIV-1 drug resistance mutations. Amplicons were sequenced and interpreted by Stanford HIVdb interpretation algorithm 8.4. We assessed treatment outcomes by evaluating clinical outcome and viral suppression at the end of the follow-up period in October 2019.

Results

PDR testing was successful in 197 of 200 samples. The overall NNRTI- PDR prevalence was 13.7% (27/197). The prevalence of intermediate or high level NNRTI- PDR was 11.2% (22/197). The most common mutation was K103N (5.6%, 11/197), followed by Y181C (3.6%, 7/197). In one case, we detected an NRTI resistance mutation (M184V), in combination with multiple NNRTI resistance mutations. All HIV-1 isolates analyzed were of subtype C. Of the 27 patients with NNRTI- PDR, 9 were still alive, on ART, and virally suppressed at the end of follow-up.

Conclusion

The prevalence of NNRTI- PDR was above the critical level of 10% suggested by the Global Action Plan on HIV Drug Resistance. The distribution of drug resistance mutations was similar to that seen in previous studies from the region, and further supports the introduction of integrase inhibitors in first-line treatment in Malawi. Furthermore, our findings underline the need for continued PDR surveillance and pharmacovigilance in Sub-Saharan Africa.
Literature
6.
go back to reference Ministry of Health Malawi. Malawi_Integrated_HIV_Program_Report_2018_Q3_appendices. Ministry of Health Malawi. Malawi_Integrated_HIV_Program_Report_2018_Q3_appendices.
11.
go back to reference Liu Tommy F, Shafer Robert W. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis. 2006;42:1608–18.CrossRef Liu Tommy F, Shafer Robert W. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis. 2006;42:1608–18.CrossRef
Metadata
Title
Pretreatment resistance mutations and treatment outcomes in adults living with HIV-1: a cohort study in urban Malawi
Authors
F. Neuhann
A. de Forest
E. Heger
A. Nhlema
C. Scheller
R. Kaiser
H. M. Steffen
H. Tweya
G. Fätkenheuer
S. Phiri
Publication date
01-12-2020
Publisher
BioMed Central
Published in
AIDS Research and Therapy / Issue 1/2020
Electronic ISSN: 1742-6405
DOI
https://doi.org/10.1186/s12981-020-00282-3

Other articles of this Issue 1/2020

AIDS Research and Therapy 1/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine